Segment Data

3 Months Ended

Dec. 31, 2012

Segment Data

Note 4 – Segment Data

The Company’s organizational structure is based upon its three principal business segments: BD Medical (“Medical”), BD Diagnostics (“Diagnostics”) and BD Biosciences (“Biosciences”). These segments are strategic businesses that are managed separately because each one develops, manufactures and markets distinct products and services. The Company evaluates performance of its business segments and allocates resources to them primarily based upon operating income. Segment operating income represents revenues reduced by product costs and operating expenses. Financial information for the Company’s segments was as follows:

	Three Months Ended December 31,
	2012			2011
Revenues (A)
Medical	$	983,373		$	950,397
Diagnostics		651,925			620,743
Biosciences		264,894			260,580
	$	1,900,192		$	1,831,720
Segment Operating Income
Medical	$	288,182		$	253,735
Diagnostics		170,009			165,364
Biosciences		65,042			61,156
Total Segment Operating Income		523,233			480,255
Unallocated Items (B)		(157,537	)		(157,813	)
Income from Continuing Operations Before Income Taxes	$	365,696		$	322,442

(A) Intersegment revenues are not material.

(B) Includes primarily interest, net; foreign exchange; corporate expenses; and share-based compensation expense.

	Three Months Ended December 31,
	2012		2011
Revenues by Organizational Units
BD Medical
Medical Surgical Systems	$	535,938	$	522,308
Diabetes Care		242,802		225,920
Pharmaceutical Systems		204,633		202,169
		983,373		950,397
BD Diagnostics
Preanalytical Systems		334,767		316,622
Diagnostic Systems		317,158		304,121
		651,925		620,743
BD Biosciences		264,894		260,580
	$	1,900,192	$	1,831,720

Revenues by geographic areas were as follows:

	Three Months Ended December 31,
	2012		2011
Total Revenues
United States	$	830,101	$	806,218
International		1,070,091		1,025,502
	$	1,900,192	$	1,831,720